Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND-ND daprodustat versus darbepoetin alfa in non-dialysis CKD anemia
NL-OMON50351Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2017
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in anemia of renal disease comparing Daprodustat with Darbepoetin alfa (2 arms). Primary endpoints: Time to first adjudicated major adverse cardiovascular event and Mean change in hemoglobin. Started Nov 2017; status: active, not recruiting.
02
Drugs
daprodustatdarbepoetin alfa
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on NL-OMON50351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50351.